Abstract
The aim of this study was to determine if Rituximab coated Biodegradable Nanoparticles (BNPs) loaded with Chlorambucil and Hydroxychloroquine could induce apoptosis of B-Chronic Lymphocytic Leukemia (B-CLL), MEC-1 and BJAB cells in vitro and evaluate their toxic and therapeutic effects on a Human/Mouse Model of Burkitt Lymphoma at an exploratory, proof of concept scale. We found that Rituximab-Chlorambucil-Hydroxychloroquine BNPs induce a decrease in cell viability of malignant B cells in a dose-dependent manner. The mediated cytotoxicity resulted from apoptosis, and was confirmed by monitoring the B-CLL cells after Annexin V/propidium iodide staining. Additional data revealed that these BNPs were non toxic for healthy animals, and had prolonged survival in this mice model of human lymphoma.
Keywords: B cells, CLL, lymphoma, nanoparticles, chlorambucil, hydroxychloroquine, rituximab.
Current Clinical Pharmacology
Title:Exploratory Study on the Effects of Biodegradable Nanoparticles with Drugs on Malignant B Cells and on a Human/Mouse Model of Burkitt Lymphoma
Volume: 5 Issue: 4
Author(s): Gustavo H. Marin, Eduardo Mansilla, Nelly Mezzaroba, Sonia Zorzet, Luis Nunez, Gustavo Larsen, Jose M. Tau, Alberto Maceira, Ruben Spretz, Carol Mertz, Sabrina Ingrao, Claudio Tripodo, Francesco Tedesco and Paolo Macor
Affiliation:
Keywords: B cells, CLL, lymphoma, nanoparticles, chlorambucil, hydroxychloroquine, rituximab.
Abstract: The aim of this study was to determine if Rituximab coated Biodegradable Nanoparticles (BNPs) loaded with Chlorambucil and Hydroxychloroquine could induce apoptosis of B-Chronic Lymphocytic Leukemia (B-CLL), MEC-1 and BJAB cells in vitro and evaluate their toxic and therapeutic effects on a Human/Mouse Model of Burkitt Lymphoma at an exploratory, proof of concept scale. We found that Rituximab-Chlorambucil-Hydroxychloroquine BNPs induce a decrease in cell viability of malignant B cells in a dose-dependent manner. The mediated cytotoxicity resulted from apoptosis, and was confirmed by monitoring the B-CLL cells after Annexin V/propidium iodide staining. Additional data revealed that these BNPs were non toxic for healthy animals, and had prolonged survival in this mice model of human lymphoma.
Export Options
About this article
Cite this article as:
H. Marin Gustavo, Mansilla Eduardo, Mezzaroba Nelly, Zorzet Sonia, Nunez Luis, Larsen Gustavo, M. Tau Jose, Maceira Alberto, Spretz Ruben, Mertz Carol, Ingrao Sabrina, Tripodo Claudio, Tedesco Francesco and Macor Paolo, Exploratory Study on the Effects of Biodegradable Nanoparticles with Drugs on Malignant B Cells and on a Human/Mouse Model of Burkitt Lymphoma, Current Clinical Pharmacology 2010; 5 (4) . https://dx.doi.org/10.2174/157488410793352058
DOI https://dx.doi.org/10.2174/157488410793352058 |
Print ISSN 1574-8847 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3938 |
Related Articles
-
Cell Death in Mammalian Development
Current Pharmaceutical Design DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design Anti-Genes: siRNA, Ribozymes and Antisense
Current Pharmaceutical Biotechnology Current Biological Therapies for Inflammatory Bowel Disease
Current Pharmaceutical Design Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design Targeting B Cells in SLE: The Experience with Rituximab Treatment (Anti-CD20)
Endocrine, Metabolic & Immune Disorders - Drug Targets Relevance of Sphingolipids in the Pleiotropic Protective Effects of High-Density Lipoproteins
Current Pharmaceutical Design Challenges in the Management of Paediatric Febrile Neutropenia
Current Pediatric Reviews The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design Regulatory T Cell Counts and Development of Malignancy in Patients with HIV Infection
Current HIV Research Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets Involvement of Cannabinoids in Cellular Proliferation
Mini-Reviews in Medicinal Chemistry Mitochondria and Organismal Longevity
Current Genomics Anticancer Antifolates: Current Status and Future Directions
Current Pharmaceutical Design Molecular Docking, Synthesis and CNS Activity of Some Novel 1, 4-Benzodiazepine Derivatives
Letters in Drug Design & Discovery Structural Aspects of Peptides with Immunomodulating Activity
Mini-Reviews in Medicinal Chemistry The Functions of Heparanase in Human Diseases
Mini-Reviews in Medicinal Chemistry Role of Cytokines in the Pathophysiology of Acute Graft-Versus-Host Disease (GVHD)– Are Serum/Plasma Cytokines Potential Biomarkers for Diagnosis of Acute GVHD Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)?
Current Stem Cell Research & Therapy